PTC Therapeutics, Inc.'s Revenue Growth Forecast Sparks Concern Over Sustained Growth Potential
PTC Therapeutics missed analyst estimates, with revenues of US$807m and a statutory loss per share (eps) of US$4.73 falling 2.1% and 6.2% below expectations, respectively. The company's analysts have updated their earnings model, forecasting revenues of US$947.4m in 2025, which would be a 17% improvement in revenue compared to the last 12 months. However, the loss per share is expected to greatly reduce in the near future, narrowing 92% to US$0.37.
- The analysts' mixed signals on PTC Therapeutics' growth potential raise questions about whether the company can sustain its revenue growth and overcome its historical challenges.
- Will the slowing down of PTC Therapeutics' revenue growth impact its competitive position in a market dominated by companies with higher growth rates?